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Chemokine receptors CCR5 and CXCR4 are considered the main coreceptors for
initial HIV infection, replication and transmission, and subsequent AIDS
progression. Over the years, other chemokine receptors, belonging to the family
of G protein-coupled receptors, have also been identiﬁed as candidate
coreceptors for HIV entry into human host cells. Amongst them, CXCR7, also
known as atypical chemokine receptor 3 (ACKR3), was suggested as a
coreceptor candidate capable of facilitating both HIV-1 and HIV-2 entry in vitro.
In this study, a cellular infection model was established to further decipher the
role of CXCR7 as an HIV coreceptor. Using this model, CXCR7-mediated viral
entry was demonstrated for several clinical HIV isolates as well as laboratory
strains. Of interest, the X4-tropic HIV-1 HE strain showed rapid adaptation
towards CXCR7-mediated infection after continuous passaging on CD4- and
CXCR7-expressing cells. Furthermore, we uncovered anti-CXCR7 monoclonal
antibodies, small molecule CXCR7 inhibitors and the natural CXCR7 chemokine
ligands as potent inhibitors of CXCR7 receptor-mediated HIV entry and
replication. Even though the clinical relevance of CXCR7-mediated HIV
infection remains poorly understood, our data suggest that divergent HIV-1 and.e00557
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environment, which warrants further investigation.
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1. Introduction
Human immunodeﬁciency virus (HIV) is the causal agent of the disease known as
acquired immune deﬁciency syndrome (AIDS). HIV/AIDS was discovered 35 years
ago and by now up to 40 million people worldwide are living with this immunosup-
pressive disease with still around 2 million new HIV infections every year [1, 2].
The viral entry of HIV-1 and HIV-2 occurs via the initial attachment of the HIV en-
velope glycoprotein (gp120) subunits to CD4 molecules on the host cell surface,
thereby exposing the coreceptor binding site. Subsequently, the CD4-activated
gp120 subunits typically interact with either one of the two chemokine receptors,
CXC Chemokine Receptor 4 (CXCR4) or CC Chemokine Receptor 5 (CCR5),
both primary coreceptors in the HIV entry process. HIV strains that infect host cells
using the CCR5 coreceptor are known as M-tropic, non-syncytium-inducing, CCR5-
tropic (R5) viruses, while infections via the CXCR4 coreceptor occur with T-tropic,
syncytium-inducing, CXCR4-tropic (X4) HIV strains. Furthermore, there are HIV
strains that can bind both CCR5 and CXCR4, the so-called dual-tropic strains. R5
strains are predominant early on in HIV infection, whereas X4 strains are linked
with later disease progression [3, 4, 5, 6, 7]. Several reports have now indicated
an increase of HIV-1 strains that predominantly use CXCR4 as a coreceptor for virus
attachment and entry. These X4 HIV-1 strains are associated with rapid disease pro-
gression towards AIDS in infected individuals. In addition, a faster clinical course is
also well-documented for individuals infected with dual-tropic (most likely X4)
HIV-1 strains [8, 9, 10].
Over the years, multiple other chemokine receptors, aside from CCR5 and CXCR4,
were uncovered as alternative coreceptors in the HIV entry process, albeit with vary-
ing potencies. Examples of chemokine receptors also serving as HIV coreceptors are
CCR3, CX3CR1, CXCR3, CXCR5, CXCR6 and CXCR7 [11, 12, 13, 14, 15, 16,
17]. The latter chemokine receptor CXCR7, also called Atypical Chemokine Recep-
tor 3 (ACKR3), is the focus of this study. Importantly, CXCR7 and CXCR4 share
CXCL12 as their natural chemokine ligand. In addition, the chemokine CXCL11
is also able to bind and activate CXCR7 [18, 19].
Anti-CXCR7 monoclonal antibody (mAb) clones 8F11-M16 and 11G8 have proven
to be eﬀective in preventing binding of the natural CXCR7 chemokine ligands
CXCL11 and CXCL12 to their cognate receptor [19, 20]. The small molecules
CCX771 and VUF11207 were described to interfere with CXCL12-CXCR7 bindingon.2018.e00557
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TC14012, initially discovered as a highly potent CXCR4 antagonist, was also shown
to block CXCL12 binding to CXCR7 and to induce CXCR7 internalization,
although with lower potency [22, 23, 24, 25]. Also, the natural chemokine ligands
of CXCR4 and CCR5 have been shown to speciﬁcally inhibit HIV entry [26, 27,
28, 29].
The chemokine receptors CXCR7 and CXCR4 not only share their natural ligand
CXCL12, they also tend to heterodimerize in cells when co-expressed [18, 30].
These two ﬁndings suggest a possible role for CXCR7 as an alternative coreceptor
for HIV strains, for instance due to the adaptation of CXCR4-using viruses over
time, ultimately enabling them to use CXCR7 as an additional coreceptor. Therefore,
in this study, we evaluated the role of CXCR7 as an alternative HIV coreceptor and
investigated to what extent CXCR4-using HIV strains could use CXCR7 as corecep-
tor. To this end, an in vitro CXCR7-speciﬁc cellular infection model using human
glioblastoma cells (U87-MG) was ﬁrst established. Further, we evaluated whether
X4-tropic strains could shift towards CXCR7 coreceptor use over time. To ulti-
mately conﬁrm the role of CXCR7 as an HIV coreceptor, CXCR7-targeting mono-
clonal antibodies (mAbs) (clones 8F11-M16, 10D1-J16 and 11G8), small molecule
CXCR7 inhibitors (CCX771, VUF11207 and TC14012) and the natural CXCR7
chemokine ligands (CXCL11 and CXCL12) were applied in the infection model
to demonstrate speciﬁc CXCR7 receptor-mediated infection. This also allowed to
directly compare the antiviral potency of these three diﬀerent classes of compounds.
Fig. 1 illustrates how CD4- and CXCR7-expressing U87 cells were utilized to reveal
the role of CXCR7 as an alternative HIV coreceptor and to uncover the potential
inhibitory eﬀect of diﬀerent classes of CXCR7-targeting ligands on viral entry
and replication of X7 HIV-1 and HIV-2 strains.2. Materials and methods
2.1. Cell cultures, plasmids and HIV strains
The human glioblastoma U87 cell line expressing human CD4 (U87.CD4) was
kindly provided by Dr. D.R. Littman (Skirball Institute of Biomolecular Medicine,
New York, NY, USA). U87-MG cells without CD4 were obtained from the Amer-
ican Type Culture Collection (Rockville, MD, USA). HIV-1 HE strain (subtype B)
was initially isolated from a Belgian AIDS patient in 1987 [31]. The primary clinical
isolate NPO3 classiﬁed as HIV-1 subtype CRF01 AE was kindly provided by Dr. J.
Lathey (then at BBI Biotech Research Laboratories, Gaithersburg, MD, USA). The
HIV-2 EHO isolate was isolated from peripheral blood lymphocytes of a patient
from Ivory Coast with full-blown AIDS [32].on.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 1. Schematic representation of an in vitro HIV infection model using U87.CD4.CXCR7 cells for the
identiﬁcation of CXCR7 coreceptor-speciﬁc inhibitors.
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CXCR7-speciﬁc monoclonal antibodies (mAbs), clones 8F11-M16 and 10D1-J16
were obtained from BioLegend (San Diego, CA, USA) and clone 11G8 was ob-
tained from R&D Systems (Minneapolis, MN, USA). ChemoCentryx (Mountain
View, CA, USA) kindly provided the small molecule CXCR7 inhibitor CCX771.
The CXCR7 ligands VUF11207 and TC14012 were obtained from Tocris Biosci-
ence (Bristol, UK). CXCL11 and CXCL12, the natural CXCR7 chemokine ligands,
were purchased from PeproTech (Rocky Hill, NJ, USA).2.3. Stable transfection of U87-MG and U87.CD4 cells with
CXCR7 wildtype
Brieﬂy, the pTEJ-8 expression vectors encoding wild-type CXCR7, kindly provided
by Thue W. Schwartz (University of Copenhagen, Denmark), were cotransfected
with the pPUR selection vector encoding puromycin resistance (Clontech Labora-
tories, Palo Alto, CA, USA) into U87.CD4 or U87-MG cells by the use of FuGENE
HD transfection reagent (Promega, USA). After puromycin (2 mg ml1) selection,
CXCR7-expressing cells were isolated from the puromycin-resistant cell cultureson.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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(BioLegend, San Diego, CA, USA) and subsequent magnetic separation of chemo-
kine receptor-positive cells with sheep anti-mouse immunoglobulin G (IgG)-conju-
gated M450 Dynabeads (ThermoFisher Scientiﬁc, Waltham, MA, USA). The
transfected cells were cultured under selection in Dulbecco’s modiﬁed Eagle’s me-
dium (DMEM; ThermoFisher Scientiﬁc) containing 10% fetal bovine serum (FBS;
ThermoFisher Scientiﬁc), 0.01 M HEPES buﬀer (ThermoFisher Scientiﬁc), 0.2 mg
ml1 Geneticin (G-418 sulfate; ThermoFisher Scientiﬁc), and 1 mg ml1 puromycin
(Sigma-Aldrich, St. Louis, MO, USA).2.4. Flow cytometry-based cell surface receptor staining with
ﬂuorescently labeled mAbs
U87 cells were ﬁrst digested using 0.25% trypsin/EDTA and resuspended in culture
medium (DMEM supplemented with 10% FBS and 1% HEPES), followed by a 2 h
incubation period to allow for reappearance of receptor expression on the cell sur-
face. U87 cells were then washed once with phosphate-buﬀered saline (PBS; Ther-
moFisher Scientiﬁc) containing 2% FBS. Cells were incubated for 30 min on ice
with PE-conjugated anti-CXCR7 mAb clone 8F11-M16 (BioLegend, San Diego,
CA, USA), PE-conjugated anti-CD4 mAb clone SK3 (Biolegend, San Diego, CA,
USA) or PE-labeled anti-CXCR4 mAb clone 12G5 (BD Biosciences, San Diego,
CA, USA) in PBS containing 2% FBS. The negative controls used in the staining
experiments were the following isotype controls from BD Biosciences, mouse
IgG1 (clone MOPC-21), mouse IgG2a (clone G155-178) and mouse IgG2b (clone
555743). Thereafter, the cells were washed twice with PBS, ﬁxed in 1% paraformal-
dehyde (PFA) in PBS and analyzed on a FACSCalibur ﬂow cytometer (BD, San
Jose, CA, USA) in combination with FlowJo software.
For the competition experiment between unlabeled and labeled anti-CXCR7 mAbs,
U87.CD4.CXCR7 cells, ﬁrst digested with 0.25% trypsin/EDTA, were washed once
with PBS/2% FBS. Then cells were resuspended at 4  106 cells ml1 in PBS/2%
FBS, wherefrom 50 ml was used for the incubation with 10 mg ml1 of the unlabeled
mAb in a U-shaped 96-well plate. Cells were washed after a 30 min incubation
period and incubated thereafter with the titrated dose of the labeled form of the
same mAb clone. After a second incubation period, cells were washed twice and
ﬁxated in 200 ml PBS/1% PFA. The resulting samples were analyzed on a FACS-
Canto ﬂow cytometer equipped with FACSDIVA software (BD, San Jose, CA,
USA) in combination with FlowJo software.2.5. HIV infection of CXCR7-transfected U87.CD4 cells
U87.CD4 cells transfected with CXCR7 were digested using 0.25% trypsin/EDTA.
These cells were washed and resuspended at 2  104 cells ml1 in culture mediumon.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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added at a ﬁnal concentration of 5,000 pg per well p24 antigen (Ag), whereas HIV-1
NPO3 was added at 20,000 pg per well to result in proper infection. To examine the
activity of CXCR7-speciﬁc mAbs and small molecules, the cells were seeded out in
24-well plates already containing the mAbs at varying concentrations (1/2 dilutions).
Then, viruses were added after a preincubation period of 20 minutes and the plates
were maintained at 37 C, 5% CO2. The cytopathic eﬀect (syncytium or giant cell
formation) in the virus-infected cell cultures was evaluated light microscopically
at 5 days after infection. Then, the supernatant was collected and analyzed for virus
content based on the p24 core Ag ELISA (PerkinElmer, Zaventem, Belgium). For
HIV-2 p27 Ag detection, the INNOTEST (Fujirebio, Temse, Belgium) was used.
Negative control U87 cells were included expressing no (U87-MG) or only one
HIV entry receptor (U87.CD4 and U87.CXCR7).
Passaging of HIV-1 HE to generate an adapted HIV-1 strain for coreceptor use was
performed as follows. U87.CD4.CXCR7 cells were infected with the HIV-1 HE
strain and cell cultures were incubated at 37 C until an extensive cytopathic eﬀect
(CPE) was observed (5 days). The culture supernatant was used for further passage
of HE strain virus in U87.CD4.CXCR7 cells to ﬁnally obtain an HIV-1 HE virus that
was better adapted to CXCR7 (and CD4) use.2.6. Flow cytometry for intracellular p24/p27 Ag detection
Five days post infection, U87.CD4.CXCR7 cells were carefully washed with cold
PBS to remove excess virus and were detached by using 0.25% trypsin-EDTA for
5 min followed by cell resuspension. The percentage of HIV-infected U87 cells
was determined by intracellular staining for HIV p24/p27 Ag, using the phycoery-
thrin (PE)-conjugated anti-p24/p27 mAb KC57-PE (Beckman Coulter, Fullerton,
California, USA). Cells were analyzed on a FACSCalibur ﬂow cytometer (BD,
San Jose, CA, USA) in combination with FlowJo software.2.7. HIV-1 entry PCR for visualization of early reverse
transcription
We used an HIV entry PCR protocol adapted from Princen et al. [33].
U87.CD4.CXCR7 cells were seeded in 24-well plates at 105 cells per well. Virus
stocks (diluted to a p24 titer of 100,000 pg ml1) were treated with 10 U ml1 of
RNase-free DNase (Roche Molecular Biochemicals, Basel, Switzerland) for 1 h at
room temperature. Compound preincubation was done for 15 min. Then the cells
in each well were infected with 5,000 pg of HIV-1 HE #10 p24. After incubation
at 37 C for 2 h, the cells were washed twice with PBS and total DNA was extracted
from the infected cells by using the QIAamp DNA mini kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. The DNA was eluted from theon.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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DNA sample was subjected to 35 cycles of HIV-1 long terminal (LTR) R/U5-
speciﬁc and 30 cycles of beta-actin-speciﬁc PCR on an Eppendorf Mastercycler
Nexus GX2. Each cycle comprised a 10-s denaturation step at 98 C, a 30-s anneal-
ing step at 66 C (HIV-1 LTR R/U5) or 72 C (beta-actin), and a 20-s extension step
at 72 C. The primers used were as follows: LTR R/U5 sense primer, 50-GGCTAAC-
TAGGGAACCCACTG-30 (nucleotides 496 to 516, according to the HIV-1 HXB-2
DNA sequence; see reference [34]); LTR R/U5 antisense primer, 50-CTGCTAGA-
GATTTTCCACACTGAC-30 (nucleotides 612 to 635); beta-actin sense primer,
50-TCTGGCGGCACCACCATGTACC-30 (nucleotides 2658 to 2679); beta-actin
anti-sense primer, 50-CGATGGAGGGGCCGGACTCG-30 (nucleotides 2961 to
2980). The reaction mixtures contained PCR buﬀer (supplied with the enzyme),
200 mM dNTP mix (New England Biolabs, Ipswich, MA, USA), 0.5 mM (each) for-
ward and reverse primers, and 0.5 U of Q5 Hot Start High-Fidelity DNA polymerase
(New England Biolabs, USA) in a total volume of 25 ml. After gel electrophoresis
through a 2.2% agarose gel (Lonza, Basel, Switzerland), we visualized the ampliﬁed
DNA fragments on a FastGene FAS V Gel Documentation System (Nippon Ge-
netics, Japan).2.8. Quantitative real-time PCR for detection of virus infection
and replication
Virus infection and replication in the U87.CD4.CXCR7 cell line was detected by a
highly sensitive HIV-speciﬁc quantitative PCR (qPCR). U87.CD4.CXCR7 cells
were seeded in 24-well microtiter plates at 25,000 cells per well and preincubated
with compounds for 15 min. Virus stocks (diluted to a p24 titer of 100,000 pg ml1)
were treated with 10 U ml1 of RNase-free DNase (Roche Molecular Biochemicals,
Basel, Switzerland) for 1 h at room temperature. The cells in each well were then in-
fected with 5,000 or 10,000 pg of HIV-1 HE #10 p24. After incubation of the HIV-
infectedU87.CD4.CXCR7 cell cultures at 37 C for 4 days, themediumwas aspirated,
the cells were washed once with PBS, and total DNA was extracted from the infected
cells with a QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). The DNA was
eluted from the QIAamp spin columns in a ﬁnal volume of 50 ml of elution buﬀer.
DNA samples were analyzed by quantitative real-time PCR with an ABI Prism
7500 fast real-time PCR system (Applied Biosystems, Foster City, CA,USA) in a ﬁnal
volume of 20 ml containing TaqMan Fast Universal PCRMasterMix (2X), noAmpEr-
ase UNG (Applied Biosystems, USA), 900 nM each forward and reverse primer, Taq-
Man probe at 250 nM, and 5 ml of template DNA. The PCR cycling conditionswere 20
s of initial denaturation at 95 C, followed by 40 thermal cycles of denaturation for 3 s
at 95 Cand annealing or extension for 30 s at 60 C. Primers and probeswere designed
with PrimerQuest (IntegratedDNATechnologies, IDT). A 86-bp fragment of theHIV-
1 long terminal repeat was ampliﬁed with primers 50-on.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
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CAACAGAC-30 (reverse) (IDT, Leuven, Belgium) and TaqMan probe 50-/FAM/
CCTCAATAA/ZEN/AGCTTGCCTTGAGTGCTTCAA-/IBFQ/-30 with double
quenching (IDT, Leuven, Belgium). The same amplicon cloned into the pIDTSmart
vector was bought from IDT to obtain a standard plasmid for quantifying the HIV
copy number in DNA samples from infected cell cultures. In each PCR experiment,
a standard curve was established with a 1:10 dilution series of known amounts of
the corresponding (HIV-1) standard plasmid, starting from 106 HIV-1 copies. These
standard curves were used to convert the respective cycle threshold (Ct) values ob-
tained for the DNA samples into the number of HIV proviral DNA copies.3. Results and discussion
3.1. Stable expression of the chemokine receptor CXCR7 in U87
glioblastoma cells as determined with speciﬁc anti-CXCR7 mAbs
In order to study CXCR7-dependent biological processes, it is important to use a
cell line that uniquely and stably expresses this receptor on its cell surface. Here,
the human glioblastoma cell line U87-MG, an adherent cell type that does not
endogenously express CXCR7, CXCR4 nor CD4 on its cellular surface, was
used to generate CXCR7-expressing cell lines. The cell lines created for this study
were [1] U87-MG cells expressing both the main HIV entry receptor CD4 and the
chemokine receptor CXCR7 (U87.CD4.CXCR7) and [2] U87-MG cells only ex-
pressing the coreceptor CXCR7 (U87.CXCR7). The U87.CD4.CXCR7 cells were
derived from previously established U87.CD4 cells, whereas U87.CXCR7 cells
originated from U87-MG cells. Both U87.CD4 and U87-MG cells were stably
transfected with CXCR7 cDNA contained in the pTEJ-8 mammalian expression
vector.
The expression level of CD4, CXCR4 and CXCR7 was demonstrated on the
diﬀerent U87 cell lines (Fig. 2). In order to validate protein expression of the three
cell surface receptors, ﬂuorescent PE-labeled mAbs were used that speciﬁcally bind
to the target membrane receptor. Flow cytometric analysis of the antibody labeling
was performed and demonstrated the purity of the original cell lines U87-MG and
U87.CD4 as well as the eﬃcient stable insertion of CXCR7 cDNA into both cell
lines (Fig. 2). For cell surface staining of CXCR7, the 8F11-M16 mAb clone was
used. As a positive control for the functionality of the PE-labeled anti-CXCR4
mAb clone 12G5, CXCR4 cell surface receptor staining was performed on
U87.CD4.CXCR4 cells.
After validation of the CXCR7-transfected cell lines, the speciﬁcity of the unlabeled
anti-CXCR7 mAb clones 8F11-M16, 10D1-J16 and 11G8 was veriﬁed (Fig. 3).
Here, we checked the speciﬁcity of the CXCR7-targeting antibodies via aon.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 2. Cellular receptor staining on U87 cells determined using ﬂow cytometry. U87-MG and U87.CD4
cells did not express chemokine receptors CXCR4 (blue) and CXCR7 (red). We show the expression of
CXCR7 on the U87.CXCR7 and U87.CD4.CXCR7 cells, examined using labeled anti-CXCR7 mAb
staining (red) compared to isotype control antibody staining (empty histogram). A control staining
was also performed on U87.CD4.CXCR4 to check for staining selectivity of the labeled anti-CXCR4
mAb clone 12G5 (blue). CD4 expression was only detected on cell lines U87.CD4, U87.CD4.CXCR4
and U87.CD4.CXCR7 (green).
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clone. All unlabeled mAbs could eﬃciently block the binding, and thus receptor
staining, of their ﬂuorescently-labeled mAb clone counterpart. Therefore, we are
conﬁdent that the mAb clones used for cellular receptor staining have the same bind-
ing speciﬁcity as compared to the clones used for blocking the CXCR7-mediated
HIV entry process.on.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 3. Anti-CXCR7 mAb clone speciﬁcity as determined on U87 cells using ﬂow cytometry. Histogram
plots of anti-CXCR7 mAb staining are shown to check for clone selectivity in competition experiments
between unlabeled and labeled anti-CXCR7 antibodies (black) from the same antibody clone. In each
histogram plot, also the mAb clone staining without preincubation with the unlabeled mAb was shown
(red). All antibody staining conditions were compared to an unstained control sample (empty histogram).
A representative staining was shown from one out of three independent experiments.
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ceptor expression levels. These cell lines are therefore well-suited to study HIV entry
processes via the CXCR7 coreceptor. Secondly, the unlabeled CXCR7-targeting
mAb clones that were used as blockers in our CXCR7-dependent HIV entry study
were proven speciﬁc for CXCR7, as shown by antibody competition experiments
with the equivalent labeled antibody.3.2. CXCR7-positive U87 cells can be eﬃciently infected by
HIV-1 and HIV-2 strains
An overview of cytopathic eﬀect (CPE) snapshots is shown for HIV strains able to
infect human host cells using CXCR7, in addition to CXCR4, as a coreceptor
(Fig. 4). From an in-house HIV infection screen, in which a representative array
of previously characterized CXCR4-using HIV-1 and HIV-2 isolates (n ¼ 30; using
100,000 pg dosing of each viral strain p24 stock solution) were tested on the
U87.CD4.CXCR7 cell line, the HIV-1 NPO3 and HIV-2 EHO clinical isolates
were picked up as potent CXCR7-using HIV strains (Supplementary File 1). Infec-
tion of CD4 and CXCR7 double positive U87 cells with HIV strains NPO3 and EHO
was eﬃcient. In addition, the HIV-1 HE #0 laboratory strain, which only caused a
weak CPE on U87.CD4.CXCR7 cells, was continuously passaged on these cells
to generate the HIV-1 HE #10 strain that caused pronounced CPE after a ﬁve day
infection period. The infection rate resulting from the HIV-1 HE #10 strain wason.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 4. Microscopic evaluation of HIV infection based on virus-induced cytopathic eﬀect (CPE). A
representative staining was shown from one out of three independent experiments. Brieﬂy, U87 cells
were infected with HIV-1 HE #0, HIV-1 HE #10, HIV-1 NPO3 or HIV-2 EHO (50,000 pg of p24/
p27 stock solution) and incubated at 37 C with 5% CO2 for 5 days. Thereafter, pictures were captured
on a Zeis Primovert inverted microscope equipped with an Axiocam ERc 5s camera.
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viral strains HIV-1 HE #0/#10, HIV-1 NPO3 and HIV-2 EHO were unable to infect
single positive U87 cells (U87.CD4 and U87.CXCR7). Thus, based on CPE imaging
data, both CD4 and CXCR7 are necessary for eﬃcient HIV infection and replication
in U87 cells.
To conﬁrm the infectious capacity of the viral strains, a ﬂow cytometry-based intra-
cellular antibody staining with a PE-labeled anti-p24/p27 mAb (clone KC57) was
performed. This allows to quantify the amount of the p24 (HIV-1) or p27 (HIV-2)
capsid proteins transcribed within the U87 host cells by the HIV replication machin-
ery. Relative percentages of intracellular HIV-1 p24 or HIV-2 p27 capsid protein
levels of the respective HIV-1 or HIV-2 virions are shown for U87.CD4.CXCR7
cells infected with the HIV-1 strains HE #0 (100,000 pg of p24 stock), HE #10
(5,000 pg) and NPO3 (20,000 pg), and the HIV-2 strain EHO (5,000 pg) (Fig. 5).
Thus, improved CXCR7-usage of the passaged HIV-1 HE #10 strain versus HIV-
1 HE #0 was conﬁrmed, in concordance with the CPE images (Fig. 4), with an
increased infectivity up to 47.8%. HIV-1 NPO3 and HIV-2 EHO also showed
very eﬃcient infectivity compared to the non-infected (NI) sample when measuringon.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
censes/by/4.0/).
Fig. 5. Infection rate of HIV-1 strains HE #0, HE #10 and NPO3, and HIV-2 strain EHO in
U87.CD4.CXCR7 cells. Quantiﬁcation of the % infection resulting from incubation of U87.CD4.CXCR7
cells with HIV-1 HE #0 (100,000 pg), HE #10 (5,000 pg), NPO3 (20,000 pg) and HIV-2 EHO (5,000 pg)
was performed via measurement of the HIV p24/p27 capsid protein transcribed by the HIV replication
machinery using an intracellular mAb staining against p24/p27. The data were obtained using ﬂow cy-
tometry (each dot plot represents % of infected cells for a given HIV strain). A representative staining
was shown from one out of three independent experiments, all resulting in comparable infection rates
for the given HIV strains. NI: non-infected.
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rate of 62.5% and 46.6%, respectively (Fig. 5).
HIV-1 and HIV-2 strains typically infect human host cells via initial attachment of
the gp120 viral envelope protein to the main HIV entry receptor CD4. Subse-
quently, binding sites open up on the gp120 protein surface that facilitate interac-
tion with a coreceptor, predominantly CCR5 or CXCR4 [4]. However, this study
provides clear evidence of HIV-1 as well as HIV-2 strains being able to infect
U87.CD4 cells lacking both CCR5 and CXCR4, but expressing the chemokine re-
ceptor CXCR7.
In conclusion, Figs. 4 and 5 show the increased infection rate of the passaged HE #10
strain in comparison to the original HE #0 strain in U87 cells co-expressing CXCR7
and CD4. Furthermore, both ﬁgures clearly show the eﬃciency of the clinical iso-
lates HIV-1 NPO3 and HIV-2 EHO to infect U87.CD4.CXCR7 cells. Our data sug-
gest that the diﬀerent HIV strains (HE #10, NPO3 and EHO), together with the
U87.CD4.CXCR7 cell line, can serve as a suitable cellular model to evaluate poten-
tial antivirals targeting the CXCR7 coreceptor.on.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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natural CXCR7 chemokine ligands block X7 HIV-1 and HIV-2
entry and replication
In the next set of experiments, anti-CXCR7 mAbs, CXCR7-targeting small mole-
cules and the natural CXCR7 chemokine ligands were evaluated as candidate inhib-
itors in the defense against HIV-1 or HIV-2 infection via coreceptor CXCR7. We
used U87.CD4.CXCR7 cells for infection and IC50 (half minimal (50%) inhibitory
concentration (IC) of an inhibitor) calculation was based on the detection of HIV-
1 p24 or HIV-2 p27 Ag quantity in the supernatant of infected cell culture using
Ag-speciﬁc ELISA assays.
The CXCR7-speciﬁc mAbs appeared very eﬃcient in inhibiting HIV infection with
HIV-1 HE #10 (5,000 pg), HIV-1 NPO3 (20,000 pg) and HIV-2 EHO (5,000 pg)
with IC50 values ranging between mid ng ml
1 to lower mg ml1 values. When
comparing anti-CXCR7 mAb clones 8F11-M16, 10D1-J16 and 11G8, the most
potent CXCR7 inhibitor was the 10D1-J16 clone, followed closely by 8F11-M16.
The 11G8 clone was the least eﬃcient blocker of CXCR7-mediated infection. These
observations imply that interaction sites of the 10D1-J16 clone with CXCR7
strongly coincide with the HIV gp120-CXCR7 interaction pattern. In addition,
HIV-1 HE #10 was most susceptible to treatment with anti-CXCR7 mAbs (Table
1). This could be attributed to the continuous passaging, and thereby the forced adap-
tation of HIV-1 HE to U87.CD4.CXCR7 cells. As a consequence, the virus entersTable 1. Anti-HIV activity proﬁle of CXCR7 inhibitors on U87.CD4.CXCR7
cells.
HIV p24/p27 Antigen ELISA Viral strains*
HE #10 (HIV-1) NPO3 (HIV-1) EHO (HIV-2)
CXCR7 inhibitors Monoclonal antibodyy
8F11-M16 0.39  0.04 2.52  1.36 1.35  0.28
10D1-J16 0.31  0.10 1.28  0.71 0.64  0.08
11G8 2.64  0.82 3.16  1.48 4.81  1.04
Small molecule/peptidez
CCX771 49.27  18.44 36.78  15.63 >5000
VUF11207 72.45  25.57 >5000 >5000
TC 14012 >5000 >5000 >5000
Chemokinez
CXCL11 32.07  6.07 74.07  8.87 25.66  8.11
CXCL12 231.84  58.78 230.71  29.25 470.26  90.01
*Virus input was as follows: 5,000 pg of HIV-1 HE #10, 20,000 pg of HIV-1 NPO3 and 5,000 pg of
HIV-2 EHO.
y IC50 in mg ml
1 required to inhibit viral p24 Ag (for HIV-1) or p27 Ag (for HIV-2) production by 50%
in U87.CD4.CXCR7 cells. Mean IC50 values with SEM from at least three independent infection exper-
iments are shown.
z IC50 in nM required to inhibit viral p24 Ag (for HIV-1) or p27 Ag (for HIV-2) production by 50% in
U87.CD4.CXCR7 cells. Mean IC50 values with SEM from at least three independent infection experi-
ments are shown.
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easiest gateway for entry inhibition.
The anti-HIV activity of the CXCR7-targeting small molecule inhibitors CCX771
and VUF11207 was dependent on the viral strain used for infection. CCX771 was
only capable of blocking HIV-1 infections with IC50 values of w50 nM for both
HIV-1 HE #10 as well as HIV-1 NPO3 (Table 1). This small chemical compound
could not block HIV-2 EHO strain infection when using compound concentrations
up to 5000 nM. The activity of VUF11207 was even narrower. For this small mole-
cule, blocking of the HIV-1 HE #10 strain with an IC50 value ofw70 nM was the
only observed activity as no IC50 value could be calculated for HIV-1 NPO3 and
HIV-2 EHO when tested up to 5000 nM. The small cyclic peptide and reported
CXCR7 agonist ligand TC14012 had no anti-HIV activity at the tested concentra-
tions (up to 5000 nM) against any of the three X7 HIV strains included in this study.
Finally, the natural CXCR7 ligands CXCL11 andCXCL12were tested as inhibitors of
CXCR7-mediated HIV entry and replication. The IC50 values of CXCL11 were in the
lower nanomolar range, going fromw30 nM for HIV-1 HE #10 and HIV-2 EHO in-
hibition tow75 nM for blocking of HIV-1 NPO3 viral entry (Table 1). In comparison,
the IC50 values of CXCL12 were generally higher withw230 nM for HIV-1 HE #10
andHIV-1NPO3, andw470 nM for HIV-2 EHO. According to recent ﬁndings from a
mutational analysis in Benredjem et al., (2016), there is no involvement of N-terminal
CXCR7 interaction residues for CXCL12 binding to the receptor extracellular surface.
CXCL11 on the other hand, relies on both N-terminal and extracellular loop contacts
for binding to CXCR7 [35]. Therefore, the improved activity proﬁle of CXCL11
compared to CXCL12 in the context of HIV gp120-CXCR7 blocking can be explained
by the increased occupancy of the CXCR7 chemokine receptor by CXCL11.
In general, small molecules tend to reside within a speciﬁed binding pocket on the re-
ceptor’s extracellular surface or bind in pockets shaped by neighboring extracellular
loops of the chemokine receptor [24, 36, 37, 38]. They can usually only span small,
delineated regions on the receptor surface for potential interference with HIV gp120-
CXCR7 binding. Thereby the lack of CXCR7-targeting small molecule inhibition of
HIV-2 EHO strain infection could be explained, because this virus presumablymakes
use of a diﬀerent binding site on the CXCR7 cellular surface to enter its host cells. We
suggest that anti-CXCR7mAbs are by deﬁnition broader neutralizing agents, because
of their larger molecular size (w150 kDa), by which they can cover more ground as it
comes to extracellular receptor surface. In addition, chemokines -with a molecular
weight of approximately 8 kDa- are larger than their small molecule counterparts
and therefore also occupy the chemokine receptor CXCR7 to a greater extent [35].
Furthermore, the chemokine ligands CXCL11 and CXCL12 also internalize the
CXCR7 receptor, so HIV particles are unable to enter the host cells due to absence
of the receptor on the cellular surface [20].on.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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CXCR7 cells can be blocked by CXCR7-speciﬁc inhibitors
Elucidation of early HIV-1 entry events into human host cells was done using a
PCR-based HIV-1 entry method. Here we used HIV-1-speciﬁc DNA as template
for HIV infection rate quantiﬁcation in contrast to the HIV-1 p24 or HIV-2 p27
Ag from supernatant samples used in the p24/p27 ELISA method. Essentially, a
semi-quantitative HIV-1 LTR R/U5-speciﬁc PCR was performed on total DNA iso-
lated from U87.CD4.CXCR7 cells at 2 h after infection with the X7 HIV-1 HE #10
strain. The synthesis of the LTR R/U5 DNA transcript, also called strong-stop DNA,
is the ﬁrst step of reverse transcription and is completed early in the infection pro-
cess, shortly after viral entry and uncoating. Total DNA was isolated from
U87.CD4.CXCR7 cells that were left untreated or were pretreated for 15 min with
the CXCR7 inhibitors 10D1-J16, CCX771 or CXCL11 at the highest dosing in
concordance with the p24 ELISA method. A DNA agarose gel was loaded with
PCR-ampliﬁed HIV-1-speciﬁc early transcribed DNA from total DNA samples iso-
lated from uninfected and infected (5,000 pg virus stock) U87.CD4.CXCR7 cells
(Fig. 6). Preincubation of U87.CD4.CXCR7 cells with a 10 mg ml1 dosing of
the anti-CXCR7 mAb clone 10D1-J16, the CCX771 small molecule CXCR7 antag-
onist at 5 mM or the CXCR7 ligand CXCL11 at 1 mM resulted in a marked decline in
the amount of HIV-1 speciﬁc LTR R/U5 DNA. With this, we conﬁrmed the anti-
viral potency of these CXCR7-targeting inhibitors with the highest aﬃnity for the
HIV coreceptor CXCR7. In addition, this emphasized the eﬃcacy of our HIV-1Fig. 6. DNA agarose gel showing HIV entry PCR on HIV LTR R/U5 and beta-actin DNA isolated from
HIV-1 HE #10 infected U87.CD4.CXCR7 cells. The eﬀect of the CXCR7 inhibitors is shown on
U87.CD4.CXCR7 cells infected with 5,000 pg of HIV-1 HE #10. In brief, CD4/CXCR7-positive U87
cells were left untreated or were initially preincubated with the CXCR7 inhibitors 10D1-J16 mAb (10
mg ml1), CCX771 (5 mM) and CXCL11 (1 mM). Thereafter, all experimental conditions, except for
the non-infected control, were infected with 5,000 pg HIV-1 HE #10. After a 2 h incubation period at
37 C, 5% CO2 the cells in each well of an experimental condition were lysed and total DNA was iso-
lated. Finally, an HIV-1 speciﬁc PCR was performed on each isolated total DNA sample to check for the
amount of proviral DNA. The PCR-ampliﬁed proviral DNA from the isolated total DNA samples was
eventually run and visualized on a 2.2% agarose gel. A full, non-adjusted image of the DNA agarose
gel is provided in the Supplementary content (Supplementary File 2).
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strain.3.5. Blocking of HIV-1 HE #10 strain infection and replication in
U87.CD4.CXCR7 cells as determined via quantitative PCR
The eﬃciency of virus infection and replication in the U87.CD4.CXCR7 cell line
was evaluated using a highly sensitive quantitative PCR (qPCR) method for absolute
quantiﬁcation of HIV copy numbers based on the standard curve method. Infection
of U87.CD4.CXCR7 cells with 5,000 pg and 10,000 pg X7 HIV-1 HE #10 strain
resulted in a dose-dependent infectivity rate with HIV copy numbers of w1,800
and w5,000 copies, respectively (Table 2).
In addition, the viral copy numbers detected in HIV-1 HE #10 strain infected (5,000
pg versus 10,000 pg) U87.CD4.CXCR7 cells that were pretreated with CXCR7 li-
gands 10D1-J16 (10 mg ml1), CCX771 (5 mM) or CXCL11 (1 mM) ranged from
near zero to w17 copies. Consequently, a maximal inhibitory eﬃciency was ob-
tained with these compounds, when compared to the infected, untreated sample
for each virus input. The data from these qPCR experiments conﬁrm the potencies
of the evaluated CXCR7 inhibitors that show similar inhibitory eﬃcacy when
compared to the p24 ELISA experiments. Taken together, the qPCR results along
with the results from the semi-quantitative HIV entry experiments underscore the
role for CXCR7 inhibitors as HIV entry blockers, but also for interference with
the subsequent HIV replication process.Table 2. Evaluation of CXCR7 inhibitors interfering with HIV entry/replication
using qPCR.




Non-infected e 0.00  0.00 e
HIV-1 HE #10 5,000 pg e 1767.97  753.01 e
10D1-J16 11.56  0.95 99.23  0.28
CCX771 8.38  0.82 99.40  0.30
CXCL11 0.00  0.00 100.00  0.00
HIV-1 HE #10 10,000 pg e 4968.16  714.36 e
10D1-J16 16.84  5.43 99.67  0.06
CCX771 15.91  1.85 99.68  0.01
CXCL11 14.65  1.91 99.71  0.00
*The three most eﬃcient CXCR7 inhibitors 10D1-J16, CCX771 and CXCL11 were dosed at 10 mg
ml1, 5 mM and 1 mM, respectively, corresponding to the maximal dosing used for the p24 ELISA assay.
yViral copy numbers were derived from a standard curve created by serial dilution of known amounts of
HIV-1 LTR R/U5 cDNA containing plasmid vector. All DNA samples were analyzed in triplicate within
each qPCR experiment, and mean viral copy numbers with SEM from two biological replicates per
experimental condition are shown.
zMean values of % Inhibition with SEM are shown from two biological replicates analyzed in triplicate
within each qPCR experiment.
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In this study, CXCR7-mediated viral entry of HIV-1 and HIV-2 strains was
demonstrated experimentally using a novel in vitro cellular infection model, in
which CXCR7 was the sole chemokine receptor overexpressed on the surface
of human U87 glioblastoma cells along with CD4, the main HIV receptor. The
anti-CXCR7 mAb clones 8F11-M16, 10D1-J16 and 11G8 consistently and eﬃ-
ciently inhibited CXCR7-mediated HIV entry at the host cell surface, which
conﬁrmed that the viral entry genuinely occurred via CXCR7. The natural
CXCR7 chemokine ligands CXCL11 and CXCL12 also eﬃciently blocked HIV
entry via CXCR7. The antiviral potency of these chemokines might occur via
an inhibition mechanism that combines multi-site extracellular surface blocking
and removal of CXCR7 from the cell surface via receptor endocytosis. The less
consistent inhibition proﬁle of the tested small molecule CXCR7 ligands
CCX771, VUF11207 and TC14012 could instead be attributed to their smaller
molecular size and deviant amino acid interactions with CXCR7 compared to
gp120-CXCR7 interaction sites. Nevertheless, the three classes of gp120-
CXCR7 interfering ligands identiﬁed within this study make up useful starting
points for counteracting HIV strains and clinical isolates that have adapted to
CXCR7 coreceptor use during early infection.
Of interest, the CXCR7 inhibitor CCX771 was recently described to interfere with
CXCL12-directed migration of CXCR7-positive CD14þ CD16þ monocytes of
HIV-infected people into the CNS, which can result in a neurodegenerative dis-
ease termed NeuroAIDS [39]. Under normal physiological conditions, double pos-
itive CD14þ CD16þ monocytes constitute only 10e15% of the total monocyte
population. However, an increase in these nonclassic monocytes is associated
with several pathologies, including HIV infection [40, 41]. Aside from the role
of CXCR7 in CXCL12-guided cell migration across the blood brain barrier
(BBB), the higher CXCR7 cell surface expression on the HIV-susceptible
CD14þ CD16þ monocytes might increase the likelihood of CXCR7 coreceptor
use in subsequent infection cycles of CD14þ CD16þ monocytes. A major chal-
lenge, however, lies in assessing the role of CXCR7 as coreceptor in human
monocyte (sub)populations, since diﬀerent monocyte populations carry varying
subsets of a whole range of candidate HIV coreceptors on their cell surface [42,
43]. Besides monocytes, CXCR7 was also expressed on the cell surface of other
human leukocytes, among which subsets of B cells and T cells. For instance,
CXCR7-expressing B cells were elevated in HIV-positive individuals [44, 45].
In addition, increased CXCR7 expression on CD4þ T cells was associated with
immune dysregulation in children with autism [46]. The latter observations in
deﬁned B and T cell subpopulations could point to possible CXCR7 coreceptor
use in case of immune imbalance.on.2018.e00557
ors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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CXCR7 with regard to CXCL12/CXCR4/CXCR7 downstream signaling [47, 48,
49, 50, 51, 52, 53] within the last decade strengthens the presumption that
CXCR7 is used by more HIV strains than we can currently comprehend. In conclu-
sion, the ﬂexibility of HIV particles to adapt to a broader range of coreceptors or to
an alternative coreceptor use could be strongly underestimated when keeping in
mind the intimate CXCR4/CXCR7 relationship and the currently increasing circula-
tion of CXCR4-using viruses in South American and Asian countries, which implies
a coinciding increase in CXCR7-using HIV strains [8, 9].Declarations
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